Sanofi Underpins Vaccine Strategy With New Manufacturing Facilities
Sanofi's major investments in vaccine manufacturing are continuing with the expansion of its Toronto, Canada facility, to be completed in 2021.
You may also be interested in...
A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.
Mereo BioPharma’s completed private placement in the US will support clinical studies of its candidate immuno-oncology product etigilimab and a later-stage anti-sclerotin antibody product with potential in the treatment of brittle bone disease.
Novartis will not start to compete in the increasingly crowded US multiple sclerosis marketplace with ofatumumab this month, as regulators extend the review process for the B-cell depleting therapy until September.